AP2015008898A0 - Prodrug derivatives of substituted triazolopyridines - Google Patents

Prodrug derivatives of substituted triazolopyridines

Info

Publication number
AP2015008898A0
AP2015008898A0 AP2015008898A AP2015008898A AP2015008898A0 AP 2015008898 A0 AP2015008898 A0 AP 2015008898A0 AP 2015008898 A AP2015008898 A AP 2015008898A AP 2015008898 A AP2015008898 A AP 2015008898A AP 2015008898 A0 AP2015008898 A0 AP 2015008898A0
Authority
AP
ARIPO
Prior art keywords
prodrug derivatives
substituted triazolopyridines
triazolopyridines
substituted
prodrug
Prior art date
Application number
AP2015008898A
Other languages
English (en)
Inventor
Ildiko Terebesi
Ulrich Lücking
Michael Brüning
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AP2015008898A0 publication Critical patent/AP2015008898A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2015008898A 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines AP2015008898A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Publications (1)

Publication Number Publication Date
AP2015008898A0 true AP2015008898A0 (en) 2015-12-31

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008898A AP2015008898A0 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Country Status (35)

Country Link
US (1) US9586958B2 (pt)
EP (1) EP3008062B1 (pt)
JP (1) JP2016526534A (pt)
KR (1) KR20160019492A (pt)
CN (1) CN105377848A (pt)
AP (1) AP2015008898A0 (pt)
AR (1) AR096585A1 (pt)
AU (1) AU2014280356A1 (pt)
CA (1) CA2914745A1 (pt)
CL (1) CL2015003605A1 (pt)
CR (1) CR20150659A (pt)
CU (1) CU20150176A7 (pt)
DK (1) DK3008062T3 (pt)
DO (1) DOP2015000299A (pt)
EA (1) EA201600002A1 (pt)
ES (1) ES2626790T3 (pt)
HK (1) HK1221955A1 (pt)
HR (1) HRP20170717T1 (pt)
HU (1) HUE033131T2 (pt)
IL (1) IL242847A0 (pt)
LT (1) LT3008062T (pt)
MA (1) MA38654B1 (pt)
MX (1) MX2015017119A (pt)
NI (1) NI201500176A (pt)
PE (1) PE20160156A1 (pt)
PH (1) PH12015502746A1 (pt)
PL (1) PL3008062T3 (pt)
PT (1) PT3008062T (pt)
RS (1) RS56034B1 (pt)
SG (1) SG11201509858QA (pt)
SI (1) SI3008062T1 (pt)
TN (1) TN2015000545A1 (pt)
UY (1) UY35610A (pt)
WO (1) WO2014198647A2 (pt)
ZA (1) ZA201508868B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
MA44629A (fr) * 2016-04-04 2021-03-24 Chemocentryx Inc Antagonistes de c5ar solubles
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263566C (en) 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
AP1444A (en) 1997-05-28 2005-07-18 Aventis Pharma Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
US7226941B2 (en) 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
ATE465164T1 (de) 2006-05-31 2010-05-15 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
EP2212326A1 (en) 2007-08-23 2010-08-04 AstraZeneca AB 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EP2396324A1 (en) 2009-02-13 2011-12-21 Fovea Pharmaceuticals Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
KR20140025470A (ko) * 2011-04-21 2014-03-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 트리아졸로피리딘
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
KR20150040845A (ko) * 2012-07-10 2015-04-15 바이엘 파마 악티엔게젤샤프트 치환된 트리아졸로피리딘을 제조하는 방법
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的***并吡啶类
EA201501175A1 (ru) * 2013-06-10 2016-10-31 Байер Фарма Акциенгезельшафт Новые соединения для лечения злокачественного новообразования
KR20160018534A (ko) * 2013-06-11 2016-02-17 바이엘 파마 악티엔게젤샤프트 Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물

Also Published As

Publication number Publication date
HRP20170717T1 (hr) 2017-07-28
ZA201508868B (en) 2017-08-30
CN105377848A (zh) 2016-03-02
LT3008062T (lt) 2017-06-12
CU20150176A7 (es) 2016-05-30
NI201500176A (es) 2016-01-06
IL242847A0 (en) 2016-02-01
WO2014198647A3 (en) 2015-02-05
RS56034B1 (sr) 2017-09-29
PT3008062T (pt) 2017-06-07
SG11201509858QA (en) 2015-12-30
KR20160019492A (ko) 2016-02-19
PL3008062T3 (pl) 2017-08-31
MX2015017119A (es) 2016-04-06
AU2014280356A1 (en) 2015-12-24
SI3008062T1 (sl) 2017-06-30
CL2015003605A1 (es) 2016-06-24
EP3008062A2 (en) 2016-04-20
DK3008062T3 (en) 2017-06-12
AR096585A1 (es) 2016-01-20
MA38654B1 (fr) 2018-11-30
TN2015000545A1 (en) 2017-04-06
HUE033131T2 (en) 2017-11-28
PE20160156A1 (es) 2016-04-20
EA201600002A1 (ru) 2016-06-30
UY35610A (es) 2015-01-30
ES2626790T3 (es) 2017-07-26
US9586958B2 (en) 2017-03-07
CR20150659A (es) 2016-01-29
CA2914745A1 (en) 2014-12-18
EP3008062B1 (en) 2017-04-05
WO2014198647A2 (en) 2014-12-18
PH12015502746A1 (en) 2016-03-21
HK1221955A1 (zh) 2017-06-16
US20160207915A1 (en) 2016-07-21
DOP2015000299A (es) 2016-03-15
JP2016526534A (ja) 2016-09-05

Similar Documents

Publication Publication Date Title
HK1215795A1 (zh) 鵝膏毒素衍生物
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1223090A1 (zh) -氮雜吲哚衍生物
HRP20181710T1 (hr) Uporaba derivata benzimidazol-prolina
RS56211B1 (sr) Oksohinazolinil-butanamid derivati
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
PT3087076T (pt) Derivados de imidazopirazinona
HK1221955A1 (zh) 取代的***並吡啶的前體藥物衍生物
HK1213566A1 (zh) 新的四唑酮衍生物
GB201314965D0 (en) Spirocyclic derivatives
GB201314961D0 (en) Spirocyclic derivatives